IN8bio Reports Updated Glioblastoma Data at SNO 2026 Demonstrating Median Overall Survival of 20.9 Months and 50% Two-Year Survival with Gamma-Delta T Cell Therapy
Repeat-dose gamma-delta T cell therapy shows doubled survival in glioblastoma versus standard care.
What the company is saying
IN8bio, Inc. is highlighting updated clinical data from its INB-200 and INB-400 programs for newly diagnosed glioblastoma, presented at the 2026 Society for Neuro-Oncology Annual Meeting. The company frames its narrative around significant improvements in survival outcomes for patients receiving repeat doses of its drug-resistant gamma-delta T cells, emphasizing a 59% increase in median overall survival and a 97% increase in median progression-free survival compared to standard of care. The announcement stresses the favorable safety profile, reporting no cytokine release syndrome, ICANS, major infections, or treatment-related serious adverse events, and no treatment-related deaths. William Ho, CEO and co-founder, asserts that these results provide continued evidence of the potential for gamma-delta T cell therapies to improve patient outcomes, and references correlative analyses supporting T cell expansion and persistence. The company also mentions its broader pipeline, including INB-600 and INB-100, but provides no new data on those programs. The tone is confident and positions the results as a meaningful step forward in the field.
What the data suggests
The disclosed data shows that patients receiving repeat doses of IN8bio’s gamma-delta T cell therapy achieved a median overall survival of 20.9 months, a 59% improvement over the 13.2 months seen in standard of care controls. Median progression-free survival for the repeat-dose group was 13.0 months, up 97% from 6.6 months in the control group. At the two-year mark, 50% (7 of 14) of repeat-dose patients were alive, compared to 10% (1 of 10) in the SOC group, and both figures surpass historical NEJM benchmarks of 26.5%. The benefit was observed despite only 43% of repeat-dose patients undergoing total surgical resection, versus 80% in the SOC group. Safety data is strong, with no observed CRS, ICANS, major infections, or treatment-related serious adverse events, and no treatment-related deaths. Subgroup analysis shows INB-200 repeat dose patients had a median OS of 21.1 months and 50% two-year survival, while INB-400 repeat dose patients had a median OS of 20.9 months and 50% two-year survival. The sample size is small (17 treated patients), and the results are from Phase 1/2 studies, which limits generalizability. No financial, operational cost, or commercialisation data is provided.
Analysis
The announcement presents robust and specific clinical data from IN8bio's INB-200 and INB-400 programs, including median overall survival and progression-free survival improvements versus standard of care, as well as detailed safety outcomes. These realised results are credible and well-supported by the disclosed numbers. However, the tone is somewhat inflated by repeated references to the 'potential' of gamma-delta T cell therapies to improve outcomes, which are forward-looking and not yet proven in larger, later-stage trials. The sample size is small (17 treated patients), and while the survival data is promising, the announcement does not address next steps, regulatory timelines, or commercialisation prospects, making the path to tangible investor benefit long-term and uncertain. There is no mention of capital outlay or financial impact, but as a clinical-stage biotech, this is not a deficiency. The gap between narrative and evidence is moderate: the realised data is strong for this stage, but the language overstates the certainty of future benefit.
Risk flags
- ●The small sample size (17 treated patients, 14 in the repeat-dose group) limits statistical power and generalizability, increasing the risk that results may not hold in larger, more diverse populations.
- ●The data comes from early-phase (Phase 1/2) studies, so efficacy and safety must be validated in larger, randomized trials before regulatory or commercial milestones can be reached.
- ●No financial or operational cost data is disclosed, leaving investors unable to assess the company’s funding runway, burn rate, or capital requirements for advancing to later-stage trials.
- ●The favorable safety profile is encouraging, but longer-term and larger-scale safety data are needed to rule out rare or delayed adverse events, especially as the therapy moves into broader clinical use.
- ●There is execution risk in advancing from promising early-phase results to successful pivotal trials and eventual regulatory approval, especially given the high attrition rate in oncology drug development.
Bottom line
IN8bio’s updated clinical data for its repeat-dose gamma-delta T cell therapy in glioblastoma patients shows a doubling of median progression-free survival and a 59% increase in median overall survival compared to standard of care, with 50% two-year survival in the treated group versus 10% in controls. The safety profile is strong, with no treatment-related deaths or serious adverse events reported. However, these results are from a small, early-phase cohort, and the company has not disclosed financials or a clear regulatory path. Investors should recognize that while the clinical signals are promising, the leap to commercial value is distant and contingent on success in larger trials. The most important takeaway is that IN8bio’s therapy has demonstrated potential in a difficult-to-treat cancer, but the investment case depends on future data from larger, later-stage studies.
Announcement summary
(NASDAQ:INAB) IN8bio, Inc. announced updated clinical data from its INB-200 and INB-400 programs in newly diagnosed glioblastoma (GBM), presented at the 2026 Society for Neuro-Oncology (SNO) Annual Meeting. The updated results showed that patients receiving repeat doses of IN8bio’s drug-resistant gamma-delta (γδ) T cells achieved a final median overall survival (mOS) of 20.9 months, representing a 59% increase compared to 13.2 months in those receiving standard of care (SOC). Median progression-free survival (mPFS) for repeat-dose patients was 13.0 months, a 97% increase over the 6.6 months observed in SOC patients. At two years, 50% of patients (7 of 14) receiving repeat-dose therapy were alive, compared to 10% (1 of 10) in the SOC group. The analysis included 17 patients treated with INB-200 or INB-400 across four cancer centers: University of Alabama at Birmingham (UAB) O’Neal Comprehensive Cancer Center, The Ohio State University Wexner Medical Center, Moffitt Cancer Center, and the Cleveland Clinic. In the control (SOC) group, median PFS was 6.6 months, median OS was 13.2 months, and 10% of patients were alive at two years. For INB-200 DL1 patients, median PFS was 8.0 months, median OS was 15.7 months, and 0% were alive at two years. INB-200 repeat dose patients had a median PFS of 16.1 months, median OS of 21.1 months, and 50% (5 of 10) were alive at two years. INB-400 repeat dose patients had a median PFS of 13.0 months, median OS of 20.9 months, and 50% (2 of 4) were alive at two years. All repeat dose patients combined had a median PFS of 13.0 months, median OS of 20.9 months, and 50% (7 of 14) were alive at two years. Historical NEJM data showed a median PFS of 6.9 months, median OS of 14.6 months, and 26.5% alive at two years. Total surgical resection was performed in 43% of repeat-dose patients, compared with 80% of SOC control patients. The γδ T cell therapy demonstrated a favorable safety and tolerability profile, with no observed cytokine release syndrome (CRS), immune effector cell-associated neurotoxicity syndrome (ICANS), major infections, or treatment-related serious adverse events. No treatment-related deaths were reported. William Ho, CEO and co-founder of IN8bio, stated that the results provide continued evidence of the potential for γδ T cell therapies to improve outcomes for patients. The company’s pipeline includes INB-600, a γδ T cell engager platform, INB-100 for high-risk leukemias, and INB-200/400 for newly diagnosed GBM.
Disagree with this article?
Ctrl + Enter to submit